Evidence-Based Medicine
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 14, 2014; 20(22): 6932-6938
Published online Jun 14, 2014. doi: 10.3748/wjg.v20.i22.6932
Table 2 Baseline characteristics according to first line therapies n (%)
Standard triple therapyBismuth quadruple therapySequential therapyConcomitant therapyP value1
Mean age ± SD (yr)58.1 ± 11.658.5 ± 11.456.1 ± 11.556.9 ± 11.30.591
Male/Female (n)72/8610/1820/2124/130.150
Smoking (n)28 (17.7)4 (13.8)8 (19.5)8 (21.6)0.904
Alcohol (n)35 (22.2)7 (24.1)10 (24.4)10 (27)0.851
HTN (n)34 (21.5)5 (17.2)6 (14.6)4 (10.8)0.451
DM (n)14 (8.9)3 (10.3)2 (4.9)2 (5.4)0.845
Endoscopic finding (n)-
DU/GU55168-
CAG66181312-
IM23153-
Erosive gastritis3091815-
MALT lymphoma0020-